Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Urea transporters UT-A1 and UT-B are specialized membrane proteins belonging to the SLC14 family that facilitate the rapid movement of urea across cell membranes (NIH, 2023). UT-A1 is primarily expressed in the apical membrane of the inner medullary collecting duct, where its activity is regulated by vasopressin to facilitate urea reabsorption (PubMed, 2020). UT-B is found in the descending vasa recta and erythrocytes, where it facilitates urea recycling and protects red blood cells from osmotic stress (Wikipedia, 2024). Together, these transporters are essential for the kidney's countercurrent multiplication system, which establishes the osmotic gradient required for urine concentration and water reabsorption (NIH, 2025). Dysregulation or deficiency of these transporters is associated with clinical conditions such as the syndrome of inappropriate antidiuretic hormone secretion (SIADH), hyponatremia, and various edematous states (FASEB J, 2024). Pharmacological inhibition of UT-A1 and UT-B represents a novel therapeutic approach known as 'urearesis,' which induces osmotic diuresis (Nature Reviews Nephrology, 2015). Unlike traditional diuretics that target sodium transporters, UT inhibitors promote water excretion without causing significant electrolyte imbalances like hypokalemia or hyponatremia (NIH, 2024). Experimental small-molecule inhibitors, such as thienoquinolins and thiourea analogs, have shown promise in preclinical models for treating fluid overload and hyponatremia (PubMed, 2020). Beyond the kidney, these transporters are also expressed in the heart, brain, and testis, suggesting potential roles in cardiovascular and reproductive physiology (NIH, 2019). Consequently, they are being investigated as promising targets for a new class of sodium-sparing diuretics with unique clinical indications (NIH, 2025).
Inhibition of urea transport in the renal medulla, which disrupts the intrarenal urea gradient and leads to osmotic diuresis (urearesis) without significant electrolyte loss (Nature Reviews Nephrology, 2015; NIH, 2024).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Urea transporter UT-A1 and Urea transporter UT-B (UT-A1/UT-B).